Skip to main content

Advertisement

Log in

Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

The endocannabinoid system (EC) has emerged as a crucial mediator in a variety of pathophysiological conditions.

Aims

To evaluate: (1) whether the EC system is activated in the livers of patients with primary biliary cirrhosis (PBC); (2) if genetic variations in human EC receptor genes (CB1 and CB2) may be associated with a different phenotypic expression of the disease and response to therapy.

Methods

The expression of CB1 and CB2 receptors was studied by immunohistochemistry in liver biopsy specimens from 13 patients with PBC, and CB1 and CB2 mRNA expression was studied by real-time polymerase chain reaction testing (RT-PCR) in liver samples. In addition, genetic polymorphisms in the EC receptor gene were sought in 68 patients with PBC from Italy, 84 patients who were residents of the United States (US), and 70 controls matched for sex, age, and for geographical area with the Italian PBC patients. Genomic DNA was extracted from peripheral venous blood leucocytes with standard methods. PCR was used to amplify the coding regions of the CB1 and CB2 genes with specific primers.

Results

CB1 was markedly expressed in hepatocytes and biliary epithelial cells in the livers of patients with PBC; conversely in control liver samples, it was virtually absent. CB2 was expressed in hepatocytes and in cholangiocytes, whereas it was absent from mesenchymal cells. The mRNA of both CB1 and CB2 was detected in the PBC liver samples, as demonstrated by RT-PCR. The CB1 polymorphism (1359 G/A) was present in 26.5% of Italian patients, in 22.9% of healthy controls, and in 27.4% of patients from the US (p = n.s.). The CB2 polymorphism (188–189 AA/GG) was present in 24.4 versus 30.4% of Italian and US patients with PBC, respectively, and in 28.0% of Italian controls samples (p = n.s.). Logistic regression analysis showed that advanced histological stage and the lack of response to ursodeoxycholic acid treatment were significantly correlated with the CB1 polymorphism.

Conclusions

The EC system is markedly up-regulated in the livers of patients with PBC and it may exert a role regulating adaptive mechanisms in cholestasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3:771–84.

    Article  CAS  PubMed  Google Scholar 

  2. Woods SC. The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. Am J Med. 2007;120:S9–17.

    Article  CAS  PubMed  Google Scholar 

  3. Julien B, Grenard P, Teixeira-Clerc F, Tran Van Nhieu J, Li L, Karsak M, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 2005;128:742–55.

    Article  CAS  PubMed  Google Scholar 

  4. Caraceni P, Domenicali M, Bernardi M. The endocannabinoid system and liver diseases. J Neuroendocrinol. 2008;20(suppl 1):47–52.

    Article  CAS  PubMed  Google Scholar 

  5. Siegmund SD, Shwabe RF. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2008;294:G357–62.

    Article  CAS  PubMed  Google Scholar 

  6. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42:63–71.

    Article  CAS  PubMed  Google Scholar 

  7. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5:400–11.

    Article  CAS  PubMed  Google Scholar 

  8. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, et al. The cannabinoid system and immune modulation. J Leukoc Biol. 2003;74:486–96.

    Article  CAS  PubMed  Google Scholar 

  9. Mechoulam M, Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids. 2000;108:1–13.

    Article  CAS  PubMed  Google Scholar 

  10. Norrod AG, Puffenbarger RA. Genetic polymorphisms of the endocannabinoid system. Chem Biodivers. 2007;4:1926–32.

    Article  CAS  PubMed  Google Scholar 

  11. Gadzicki D, Muller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes. 1999;13:321–5.

    Article  CAS  PubMed  Google Scholar 

  12. Sipe JC, Arbour N, Gerber A, Beutler E. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J Leukoc Biol. 2005;78:231–8.

    Article  CAS  PubMed  Google Scholar 

  13. Berdyshev EV. Cannabinoid receptors and the regulation of the immune response. Chem Phys Lipids. 2000;108:169–90.

    Article  CAS  PubMed  Google Scholar 

  14. Neef GW, O’Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol. 2002;97:2117–9.

    Article  Google Scholar 

  15. Floreani A, Carderi I, Variola A, Rizzotto ER, Nicol J, Bergasa NV. A novel multidrug resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus. Hepatology. 2006;43:1152–4.

    Article  CAS  PubMed  Google Scholar 

  16. Wei LX, Floreani A, Variola A, El Younis C, Bergasa NV. A study of the mu opioid receptor gene polymorphism A118G in patients with primary biliary cirrhosis with and without pruritus. Acta Derm Venerol. 2008;88:323–6.

    CAS  PubMed  Google Scholar 

  17. Scheuer PJ. Primary biliary cirrhosis. Proc Roy Soc Med. 1967;60:1257–60.

    CAS  PubMed  Google Scholar 

  18. Parés A, Llorenc Caballeria, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715–20.

    Article  PubMed  Google Scholar 

  19. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut. 2008;57:1140–55.

    Article  CAS  PubMed  Google Scholar 

  20. Fernandez-Rodriguez CM, Romero J, Petros TJ, Bradshaw H, Gasalla JM, Gutierrez ML, et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int. 2004;24:477–83.

    Article  CAS  PubMed  Google Scholar 

  21. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med. 2006;12:671–6.

    Article  CAS  PubMed  Google Scholar 

  22. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 2007;21:1788–800.

    Article  CAS  PubMed  Google Scholar 

  23. Stella N. Endocannabinoid signalling in microglial cells. Neuropharmacology. 2009;56(suppl. 1):244–53.

    Article  CAS  PubMed  Google Scholar 

  24. Glass M, Northup JK. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol. 1999;56:1362–9.

    CAS  PubMed  Google Scholar 

  25. Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298–305.

    CAS  PubMed  Google Scholar 

  26. Alvaro D, Mancino MG. New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med. 2008;29:50–7.

    Article  CAS  PubMed  Google Scholar 

  27. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology. 2004;127:1565–77.

    Article  CAS  PubMed  Google Scholar 

  28. Leuchner M, Dietrich CF, You T, Seidl C, Raedle J, Hermann G, et al. Characterization of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut. 2000;46:121–6.

    Article  Google Scholar 

  29. Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol. 2007;152:734–43.

    Article  CAS  PubMed  Google Scholar 

  30. Lenman A, Fowler CJ. Interaction of ligands for the peroxisome proliferators-activated receptor γ with the endocannabinoid system. Br J Pharmacol. 2007;151:1343–51.

    Article  CAS  PubMed  Google Scholar 

  31. Zollner G, Marschall HU, Wagner M, Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm. 2006;3:231–51.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This work was partially supported by a University grant (ex 60% fund).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Annarosa Floreani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Floreani, A., Lazzari, R., Macchi, V. et al. Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis. J Gastroenterol 45, 68–76 (2010). https://doi.org/10.1007/s00535-009-0122-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-009-0122-y

Keywords

Navigation